(firstQuint)Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma.

 There have been no standard treatment in non-clear cell renal cell carcinoma.

 Retrospective studies showed sunitinib or sorafenib might be active in non-clear cell renal cell carcinoma, especially papillary type and chromophobe type.

 This study is to evaluate efficacy and safety of sunitinib in this group of patients.

.

 Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma@highlight

To evaluate the efficacy and safety of sunitinib in non-clear cell type renal cell carcinoma with the exception of pure sarcomatoid carcinoma and collecting duct carcinoma